DF 5001
Alternative Names: DF-5001Latest Information Update: 28 Dec 2023
At a glance
- Originator Dragonfly Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 05 Nov 2019 Preclinical trials in Haematological malignancies in USA (Parenteral) before November 2019
- 15 Jan 2019 Dragonfly Therapeutics enters into a collaboration with University of Texas MD Anderson Cancer Center for Solid tumours and Haematological malignancies